Leaflet LENALIDOMIDA STADA 5mg capsules

Indicated for: multiple myeloma

Route of administration: oral

Substance: lenalidomide (immunomodulator)

ATC: L04AX04 (Antineoplastic and immunomodulating agents | Immunosuppressants | Other immunosuppressants)

Precautions:
Contraception required
Contraception required

Effective contraception is required during treatment.

Contraindicated during breastfeeding
Contraindicated during breastfeeding

Do not use this medicine while breastfeeding.

Contraindicated during pregnancy
Contraindicated during pregnancy

Do not use this medicine during pregnancy.

Avoid live vaccines
Avoid live vaccines

Avoid live vaccines during treatment if contraindicated.

Immunosuppression / infection risk
Immunosuppression / infection risk

This medicine may increase the risk of infections.

Teratogenic / fetal risk
Teratogenic / fetal risk

This medicine may affect fetal development.

Lenalidomide is a medication used for the treatment of multiple myeloma, myelodysplastic syndromes, and other hematologic conditions. It works by modulating the immune system and inhibiting tumor cell growth.

The medication is taken orally, usually once daily, as part of a treatment cycle prescribed by a doctor. Regular monitoring of hematologic function is important, and precautions must be taken to avoid pregnancy.

Side effects may include fatigue, anemia, neutropenia, or skin rashes. In rare cases, deep vein thrombosis or severe allergic reactions may occur.

Lenalidomide is not recommended for pregnant women or those planning to become pregnant, as well as patients with hypersensitivity to this medication.

General data about LENALIDOMIDA STADA 5mg

  • Substance: lenalidomide
  • Date of latest medicines list: 01-06-2026
  • Product code: W67042002
  • Concentration: 5mg
  • Pharmaceutical form: capsules
  • Quantity: 21
  • Product type: Generic medicine
  • Price: 4249.73 RON
  • Prescription status: P-RF - Medicines dispensed with a medical prescription that is retained by the pharmacy and cannot be renewed.

Marketing authorisation

  • Manufacturer: PHARMADOX HEALTHCARE LTD. - MALTA
  • Holder: STADA M&D SRL - ROMANIA
  • Number: 10943/2018/02
  • Shelf life: 3 years

Concentrations available for lenalidomide

  • 10mg
  • 15mg
  • 2.5mg
  • 20mg
  • 25mg
  • 5mg
  • 7.5mg

Compensation lists for LENALIDOMIDA STADA 5mg STADA

NHP 3 (C2) - NHP oncology

Price

Copayment

Patient

4249.73 RON

1378.20 RON

2871.53 RON